NYSE:ZBH - Zimmer Biomet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$127.68 +4.18 (+3.38 %)
(As of 10/16/2018 04:00 PM ET)
Previous Close$123.50
Today's Range$123.33 - $127.80
52-Week Range$104.28 - $134.55
Volume1.48 million shs
Average Volume1.16 million shs
Market Capitalization$26.75 billion
P/E Ratio15.58
Dividend Yield0.78%
Beta1.08
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZBH
CUSIPN/A
Phone574-267-6131

Debt

Debt-to-Equity Ratio0.78
Current Ratio2.41
Quick Ratio1.25

Price-To-Earnings

Trailing P/E Ratio15.58
Forward P/E Ratio16.67
P/E Growth2.41

Sales & Book Value

Annual Sales$7.82 billion
Price / Sales3.32
Cash Flow$14.5421 per share
Price / Cash8.78
Book Value$57.96 per share
Price / Book2.20

Profitability

EPS (Most Recent Fiscal Year)$8.03
Net Income$1.81 billion
Net Margins21.67%
Return on Equity13.53%
Return on Assets5.95%

Miscellaneous

Employees18,200
Outstanding Shares203,490,000
Market Cap$26.75 billion

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Thursday, September 13th. Stockholders of record on Friday, September 28th will be paid a dividend of $0.24 per share on Wednesday, October 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.75%. The ex-dividend date is Thursday, September 27th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) released its earnings results on Friday, July, 27th. The medical equipment provider reported $1.92 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.88 by $0.04. The medical equipment provider had revenue of $2.01 billion for the quarter, compared to analysts' expectations of $1.99 billion. Zimmer Biomet had a net margin of 21.67% and a return on equity of 13.53%. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.08 earnings per share. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Friday, October 26th 2018. View Earnings Estimates for Zimmer Biomet.

How can I listen to Zimmer Biomet's earnings call?

Zimmer Biomet will be holding an earnings conference call on Friday, October 26th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8883129837.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet updated its FY18 earnings guidance on Friday, July, 27th. The company provided earnings per share (EPS) guidance of $7.60-7.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.64. The company issued revenue guidance of $7.90-8.02 billion, compared to the consensus revenue estimate of $7.98 billion.

What price target have analysts set for ZBH?

25 equities research analysts have issued 12 month price targets for Zimmer Biomet's stock. Their predictions range from $96.00 to $168.00. On average, they expect Zimmer Biomet's share price to reach $135.3333 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 2 sell ratings, 8 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018)
  • 2. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018)
  • 3. According to Zacks Investment Research, "In the past six months, Zimmer Biomet has been observed to underperform its industry. The year-over-year decline in earnings and revenues in the last reported quarter made investors jittery.  Declining sales at Knees, Hips and other segments at CER were a major disappointment. According to the company, slower pace of supply recovery and sales recapture related to major brands within the company’s Knee, Hip and S.E.T. segments marred the quarterly performance. Also, escalating costs and expenses impacted margins.  On the bright side, the company’s consistent efforts in product and renovation through research and development raise hopes. We are optimistic about synergies from the LDR buyout as well. We are also impressed by the strategic and financial goals which the combined entity expects to reach." (7/17/2018)
  • 4. Canaccord Genuity analysts commented, "We are updating our model to reflect Zimmer’s adoption of several previously disclosed new accounting standards (revenue recognition for customer contracts, reporting of pension costs, and hedging activities). The company adopted the changes effective January 1, 2018, and recently provided updated historical financials (for 2016 and 2017) to reflect a retrospective adoption of the new standards. While the new accounting policies have not resulted in any material changes to 2016 and 2017 historical results, we have nonetheless updated our model to reflect how the company will report moving forward. Additionally, we have also tweaked our forward estimates to incorporate a slightly more conservative revenue ramp in 2018/2019 and higher COGS and operating spend related to the quality/manufacturing remediation and sales channel incentives/ investments. Thus we maintain our HOLD rating and lower our price target to $121." (4/12/2018)

Who are some of Zimmer Biomet's key competitors?

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 51)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 54)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 46)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 56)
  • Mr. Kenneth R. Tripp, Sr. VP of Global Operations & Logistics

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include First Manhattan Co. (0.18%), Bank of Montreal Can (0.11%), Nisa Investment Advisors LLC (0.04%), Andra AP fonden (0.02%), DNB Asset Management AS (0.01%) and Bridge Creek Capital Management LLC (0.01%). Company insiders that own Zimmer Biomet stock include Bryan C Hanson, Chad F Phipps, David A Jr Nolan, David C Dvorak, Katarzyna Mazur-Hofsaess, Sang Yi and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which major investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Stock Yards Bank & Trust Co., Andra AP fonden, First Manhattan Co., One Capital Management LLC and BLB&B Advisors LLC. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.

Which major investors are buying Zimmer Biomet stock?

ZBH stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Nisa Investment Advisors LLC, Atria Investments LLC, Bremer Trust National Association, First Hawaiian Bank, DNB Asset Management AS, Murphy Capital Management Inc. and Town & Country Bank & Trust CO dba First Bankers Trust CO. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $127.68.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $26.75 billion and generates $7.82 billion in revenue each year. The medical equipment provider earns $1.81 billion in net income (profit) each year or $8.03 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is http://www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  639 (Vote Outperform)
Underperform Votes:  532 (Vote Underperform)
Total Votes:  1,171
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel